US hospital to start gene study for heart disease:
This article was originally published in Clinica
Executive Summary
A hospital in Michigan is the latest centre to begin trials of a new treatment for heart disease which may trigger new vessels to grow and carry blood around blocked arteries. Patients at the Henry Ford Hospital will receive the growth factor VEGF (vascular endothelial growth factor), a naturally occurring protein secreted by heart tissue lacking oxygen which has been formulated by drugs firm Genentech. The treatment could replace some angioplasty or bypass surgery procedures.